Urinary hyaluronan as a marker for the presence of residual transitional cell carcinoma of the urinary bladder

Página do item simplificado
dc.contributor.authorPasserotti, C. C.
dc.contributor.authorBonfim, A.
dc.contributor.authorMartins, JRM
dc.contributor.authorDall'Oglio, M. F.
dc.contributor.authorSampaio, L. O.
dc.contributor.authorMendes, A.
dc.contributor.authorOrtiz, V
dc.contributor.authorSrougi, M.
dc.contributor.authorDietrich, C. P.
dc.contributor.authorNader, H. B.
dc.contributor.institutionUniversidade Federal de São Paulo (UNIFESP)
dc.date.accessioned2016-01-24T12:38:16Z
dc.date.available2016-01-24T12:38:16Z
dc.date.issued2006-01-01
dc.description.abstractObjective: the purpose of this report is to evaluate the value of urinary hyaluronan (HA) as a maker of residual transitional cell carcinoma (TCC).Patients and methods: Urine samples were collected from 83 patients hospitalized for transurethral resection (TUR). Patient ages ranged from 36 to 86 years. Samples were taken both before and after surgery. HA analysis was performed using an '' ELISA-like '' fluorometric assay.Results: Patients were divided into two groups: a control group whose previous diagnosis was negative for tumors (n = 22) and another with positive diagnosis for tumors (n = 61) which was further sub-divided into with and without residual tumor. After the second procedure 47 individuals did not display residual tumor, whereas 14 (23%) did. the average HA in the control group was 8.3 mu g/L pre- and 7.1 post-operatively, hence, no change occurred (p = 0.471). in the group with TCC patients, the HA dropped from 885.5 mu g/L to 215.3 mu g/L with residual tumors and from 234.3 mu g/L to 11.2 mu g/L for those without residual tumor. Using a cut-off value of 20 mu g/L, the sensitivity to detect residual tumor is 92.9% and specificity is 83%.Conclusion: HA in addition to being one of the best markers for the initial evaluation of bladder carcinoma can be used to determine the presence of a residual tumor. This is associated with poor prognosis. (c) 2005 Elsevier B.V. All rights reserved.en
dc.description.affiliationUniversidade Federal de São Paulo, Escola Paulista Med, Disciplina Urol, São Paulo, Brazil
dc.description.affiliationUniversidade Federal de São Paulo, Escola Paulista Med, Disciplina Biol Mol, São Paulo, Brazil
dc.description.affiliationUniversidade Federal de São Paulo, Escola Paulista Med, Disciplina Endocrinol & Metabol, São Paulo, Brazil
dc.description.affiliationUnifespUniversidade Federal de São Paulo, Escola Paulista Med, Disciplina Urol, São Paulo, Brazil
dc.description.affiliationUnifespUniversidade Federal de São Paulo, Escola Paulista Med, Disciplina Biol Mol, São Paulo, Brazil
dc.description.affiliationUnifespUniversidade Federal de São Paulo, Escola Paulista Med, Disciplina Endocrinol & Metabol, São Paulo, Brazil
dc.description.sourceWeb of Science
dc.format.extent71-75
dc.identifierhttp://dx.doi.org/10.1016/j.eururo.2005.09.015
dc.identifier.citationEuropean Urology. Amsterdam: Elsevier B.V., v. 49, n. 1, p. 71-75, 2006.
dc.identifier.doi10.1016/j.eururo.2005.09.015
dc.identifier.issn0302-2838
dc.identifier.urihttp://repositorio.unifesp.br/handle/11600/28643
dc.identifier.wosWOS:000234576900012
dc.language.isoeng
dc.publisherElsevier B.V.
dc.relation.ispartofEuropean Urology
dc.rightsAcesso restrito
dc.rights.licensehttp://www.elsevier.com/about/open-access/open-access-policies/article-posting-policy
dc.subjecturinary hyaluronanen
dc.subjecttransitional cell carcinomaen
dc.subjecttransurethral resectionen
dc.titleUrinary hyaluronan as a marker for the presence of residual transitional cell carcinoma of the urinary bladderen
dc.typeArtigo
Arquivos
Coleções
Em verificação - Geral